Entrada 治療公司
US ˙ NasdaqGM ˙ US29384C1080

SecurityTRDA / Entrada Therapeutics, Inc.
InstitutionONEQ - Fidelity Nasdaq Composite Index Tracking Stock
Latest Disclosed Ownership24,723 shares
Latest Disclosed Value $ 187,894
ONEQ - Fidelity Nasdaq Composite Index Tracking Stock reports 0.49% increase in ownership of TRDA / Entrada Therapeutics, Inc.

On July 24, 2025 - ONEQ - Fidelity Nasdaq Composite Index Tracking Stock filed a NPORT-P form disclosing ownership of 24,723 shares of Entrada Therapeutics, Inc. (US:TRDA) valued at $187,895 USD as of May 31, 2025. The entity filed a previous NPORT-P on April 25, 2025 disclosing 24,603 shares of Entrada Therapeutics, Inc.. This represents a change in shares of 0.49% during the quarter. The current value of the position is $157,486 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-07-24 2025-05-31 NP ENTRADA THERAPEUTICS EC US29384C1080 24,723 120 0.49 188 -36.18 0.0025
2025-04-25 2025-02-28 NP ENTRADA THERAPEUTICS EC US29384C1080 24,603 648 2.71 294 -38.45 0.0040
2025-01-27 2024-11-30 NP ENTRADA THERAPEUTICS EC US29384C1080 23,955 168 0.71 476 13.06 0.0065
2024-10-29 2024-08-31 NP ENTRADA THERAPEUTICS EC US29384C1080 23,787 228 0.97 421 15.66 0.0062
2024-07-26 2024-05-31 NP ENTRADA THERAPEUTICS EC US29384C1080 23,559 300 1.29 364 18.57 0.0058
2024-04-24 2024-02-29 NP ENTRADA THERAPEUTICS EC US29384C1080 23,259 5,058 27.79 308 30.08 0.0051
2024-01-24 2023-11-30 NP ENTRADA THERAPEUTICS EC US29384C1080 18,201 2,416 15.31 236 1.72 0.0045
2023-10-27 2023-08-31 NP ENTRADA THERAPEUTICS EC US29384C1080 15,785 9,101 136.16 232 205.26 0.0045
2023-07-26 2023-05-31 NP ENTRADA THERAPEUTICS EC US29384C1080 6,684 18 0.27 77 -9.52 0.0017
2023-04-27 2023-02-28 NP ENTRADA THERAPEUTICS EC US29384C1080 6,666 6,666 85 0.0021
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.